SKELID

This brand name is authorized in South Africa

Active ingredients

The drug SKELID contains one active pharmaceutical ingredient (API):

1 Tiludronic acid UNII 6PNS59HP4Y - TILUDRONIC ACID

Tiludronic acid is indicated for treatment of Paget’s disease of bone (osteitis deformans). In vitro studies indicate that tiludronate disodium acts primarily on bone through a mechanism that involves inhibition of osteoclastic activity with a probable reduction in the enzymatic and transport processes that lead to resorption of the mineralized matrix. Read about Tiludronic acid

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SKELID Tablet	FDA, National Drug Code (US)	MPI, US: SPL/Old

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
M05BA05	Tiludronic acid	M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BA Bisphosphonates
Discover more medicines within M05BA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: ZA	Health Products Regulatory Authority	Identifier(s): 31/3.2/0453